Nalan for Insurance · Governed decision support
Nalan for Insurance is being explored as a governed decision-support layer for longitudinal member context, defined risk indicators, claims review and underwriting preparation. Consequential decisions remain with authorised professionals.
Decision-support concept in developmentProduction use would require validation, regulatory review, fairness testing and human decision authority.
Answer first
Nalan for Insurance is Doxyte's planned artificial intelligence (AI) decision-support concept for insurers and authorised partners. It is designed to organise appropriately consented health information, surface defined risk context, assist claims review and prepare underwriting summaries. It must not independently set a premium, deny coverage, reject a claim or determine care.
Decision support, in context
A review-ready view can bring approved member, clinical and claims context together while keeping uncertainty visible and consequential decisions with authorised professionals.
Designed around the workflow
Each capability begins as a defined use case with its own data, validation, permissions and review requirements. Release status is confirmed during discovery.
Organise appropriately authorised electronic medical record (EMR), personal health record (PHR), laboratory, medication, wearable, claims and hospitalisation information into a source-aware timeline.
A planned Nalan health risk indicator would estimate one defined question for a stated population and time horizon. It should show contributing factors, missing data, uncertainty, model version and intended use, and be validated and monitored before production deployment.
Surface potential duplicate submissions, missing documents, coding inconsistencies, rule conflicts or clinical-appropriateness questions for authorised review.
Draft underwriting summaries, identify missing information, support scenario analysis and provide governed portfolio views.
Explainable risk indicator
Nalan's planned health risk indicator is designed for one declared question, population and time horizon. It would retain permission, source context, contributing factors, missing data, uncertainty and model version so an authorised reviewer can understand both the intended use and the limitations of the estimate.
Name the outcome, intended population and time horizon instead of presenting a universal score.
Show relevant factors, missing information, uncertainty and the model version behind the estimate.
Assess calibration, performance and disparate outcomes before use and throughout the deployment.
An authorised professional remains responsible for claims, premium, coverage and underwriting decisions.
Provide appropriate routes to understand, correct and challenge information used in a consequential review.
Doxyte does not promise a lower premium; outcomes remain with the authorised insurer under applicable rules.
A governed path to production
Confirm the member permission, lawful basis, authorised role and exact intended use.
Match approved records while keeping provenance, freshness and limitations visible.
Use only models and rules approved for the intended population and purpose.
Show relevant factors, uncertainty, missing information and appropriate limitations.
A qualified claims, clinical or underwriting professional makes the consequential decision.
Retain an audit trail, support correction or appeal pathways and monitor performance and fairness.
Governance is a product capability
These boundaries guide product design and discovery. The final controls must be validated for the organisation, population, workflow and applicable obligations before production use.
Read Doxyte's security approach ↗Health information is accessed only with appropriate authorisation and for the declared purpose.
Nalan must not autonomously deny a claim, set a premium, refuse coverage or recommend withholding care.
Accuracy, calibration and disparate outcomes are evaluated across relevant populations before and during use.
Reviewers and affected members have appropriate routes to understand, correct and challenge information.
Use only information necessary for the approved workflow and apply appropriate retention controls.
Do not infer or use protected or otherwise prohibited characteristics for decision-making.
Primary reference points
These official sources inform the direction of the experience. They do not constitute a certification, regulatory approval or a substitute for implementation-specific legal, clinical or scientific review.
Reference set reviewed 31 July 2026.Questions, answered plainly
It is an organised, permissioned view of relevant longitudinal health and claims information that helps authorised teams understand context without treating any single record as the complete story.
No. Nalan is designed as decision support. Premium, coverage and claims decisions remain with authorised professionals operating under applicable rules and documented governance.
It would be a model-generated estimate for one defined question, population and time horizon. It is not a diagnosis or a general judgement about a person's health. A production use would need clear contributing factors, missing data and uncertainty information, validation, monitoring and human review.
Doxyte does not promise a lower premium. Premium and underwriting outcomes are determined by the authorised insurer under applicable rules and governance. Nalan is being designed only to organise permissioned evidence and surface reviewable signals.
It can compare approved claim attributes, documents and configured rules to surface items for review. A flag is not proof of duplication, fraud or clinical inappropriateness.
A future implementation could connect to supported Ayushman Bharat Digital Mission (ABDM) Health Claims Exchange (HCX) workflows through documented interfaces and permissions. The exact transaction scope, conformance and production status would need to be validated before launch.
Only information appropriately authorised for the declared workflow. Potential sources include supported EMR, PHR, laboratory, medication, wearable, claims and hospitalisation records.
It is a solution concept in development. Doxyte can discuss a governed design partnership, but every capability and production boundary must be confirmed before use.
Responsible intelligence for consequential workflows
Speak with Doxyte about a consent-led member, claims or underwriting-support design partnership.
Discuss a design partnership ↗